UBS Global Life Sciences Conference________________________

September 26, 2006

Safe Harbor StatementThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act’) that involve a number of risks and uncertainties. These forward-looking statements include statements relating to:

the Company’s ability to increase its client penetration for bioanalytical services,the Company’s ability to recruit subjects, the impact of discontinued operations in Miami and Ft. Myers,Canadian tax credits, industry trends,the globalization of clinical trials, cross-selling opportunities, andregulatory changes.

the Company’s future growth,Pharmaceutical industry growth and increases in clinical trials being conducted, the Company expanding its client base, the Company leveraging its existing relationships,leveraging the strong reputation of PharmaNet,the proposed amendment of the credit facility, 2006 guidance and financial metrics,

Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, our ability to leverage the strong reputation of PharmaNet, whether adverse publicity relating to PDGI’s Miami operations causes clients to select competitors, not only for early stage branded clinical trials but also for other aspects of PDGI’s business; PDGI’s ability to resolve open issues relating to its Miami property including whether it can successfully appeal and/or enjoin the Miami-Dade County Unsafe Structures Board ruling and any related fines or expenses if we are unsuccessful, the associated costs and expenses with discontinuing the Company’s operations in Miami and Ft. Myers, whether a building permit will be issued, whether PDGI will prevail in the pending land lease litigation; continued adverse publicity related to actions of the United States Senate Finance Committee; developments with respect to the SEC’s inquiry and securities class action lawsuits and derivative lawsuits; PDGI’s assessment of its current FDA inspections; PDGI’s ability to successfully achieve and manage the technical requirements of specialized clinical trial services, while complying with applicable rules and regulations; regulatory changes; changes affecting the clinical research industry; a reduction of outsourcing by pharmaceutical and biotechnology companies; PDGI's ability to compete internationally in attracting clients in order to develop additional business; cancellation of contracts; PDGI’s ability to retain and recruit new employees; PDGI's clients' ability to provide the drugs and medical devices used in its clinical trials; PDGI’s future stock price; PDGI’s financial guidance; and the national and international economic climate as it affects drug development operations. Further information can be found in PDGI's risk factors contained in its Form 10-K filed as the Company’s former name, SFBC International, Inc., with the SEC in 2006 and other filings with the Securities and Exchange Commission. We do undertake to update these forward-looking statements, and you are urged to read our filings with the Securities and Exchange Commission.

Overview

Well Positioned in the Rapidly Growing CRO IndustryDiverse Client Base

Branded pharmaceutical, biotechnology, generic drug and medical device companies

Experienced Management TeamGlobal Operations

Strategic locations accommodate complex global programs

Strong Clinical Development Expertise in all Therapeutic AreasFocus on attractive, high growth fields From study design to phase I-IV

Advanced Technology PlatformsPharmaSoft® Information Technology State-of-the-art bioanalytical laboratories

Financial StrengthCash, cash equivalents and investments in marketable securities of approximately $59.6 million at June 30, 2006

Clinical Development of PharmaceuticalsIND submitted

5 years

1.5 years

6 years

2 years

2 years

10000COMPOUNDS

250COMPOUNDS 5 COMPOUNDS

Phase I 20-100 healthy

volunteers

Phase lI 100-500 patients

Phase lIl 1000-5000

patients

FDA ReviewLarge scale

manufacturing/Phase lVClinical trials

NDA submitted

Drug discovery Pre-clinical

Synthesis11.0%

Screening Testing 15.5%

Toxicology 4.9%

Dosage formulation

8.0%

Clinical evaluation Phase l – lll

32.0%

Process Development

9.1%

Regulatory Process

4.5%

Other 2.0%

Pharma R&D Budget Allocation

~$1 billion to get a new drug to market

Clinical evaluation Phase lV

12.9%

Phase IV Post marketing &

generics

1 FDA Approved

Compound

PharmaNet Clinical Development, Software and Consulting Services

Sources: Pharma.org, Business Insights Interactive: The Pharmaceutical Market Outlook through 2005.

Well Positioned in the Rapidly Growing CRO Industry

Broader acceptanceOutsourcing of drug development services continues to grow$10 Billion market growing 14-16%(1)

R&D ResultsSuccesses are increasing the number of compounds in the development pipeline

Breadth and depth of clinical trials expandingIncreasing complexity and globalization of clinical trials driving demand for global CROs with expertise, experience, technical skills and scale

Biotechnology benefiting from the R&D expenditure growth combined with further development progress before partneringIncreased focus and requirements for post-marketing studiesProven track record of success

CROs have demonstrated that they can perform drug development faster and more cost-effectively

(1) www.ACRO.org

Diverse Client Base

Late stage

Early stage

Medium Pharma

Biotech

Large Pharma

Clinical Mix Client Mix Geographic Mix

ROW

Canada

USA

EuropeGeneric

2006E Revenue: $281 – $290 MillionBalanced clinical mix and geographic distribution of clients

Experienced Management TeamJohane Boucher-Champagne, DSAEVP, Early Clinical Development and COO of Anapharm

Ian Holmes, PhDPharmaNet SVP, Corporate Development

Mark Di IanniEVP, Strategic Initiatives

Michael E. Laird, RPhPharmaNet VP, Worldwide Business Development

James P. Burns, Jr., PhD PharmaNet SVP, Regulatory Consulting Worldwide

Mary F. Johnson, PhDPharmaNet SVP, Biostatistics

Pablo Fernandez, FFPMPharmaNet SVP, Medical Affairs

Sean P. LarkinPharmaNet EVP, Late Phase Development

Gregory M. Hockel, MBA, PhD PharmaNet SVP, Regulatory Affairs Worldwide

Robin C. SheldrickPharmaNet VP, Human Resources

Steven A. George PharmaNet SVP, Information Technology, Worldwide

Marc LeBel, PharmDEVP Bioanalytical Laboratories, CEO and President of Anapharm

Dalvir Gill, PhD PharmaNet EVP, US Clinical Research

David NatanEVP, Reporting and Analysis, Chief Accounting Officer

John P. HamillEVP and CFO

Robert Reekie, FFPMPharmaNet EVP, Operations, Europe and Asia-Pacific

Jack W. Green, PhD PharmaNet SVP, Data Management

Thomas J. Newman, MDEVP, Late Stage Development and COO PharmaNet

Client Service Worldwide: 2,000+ Employees, 30+ Offices, 26 Countries, 5 Continents

Amersfoort, NETHERLANDSBangalore, INDIABarcelona, SPAINBlue Bell, PA, USABoston, MA, USABuenos Aires, ARGENTINACharlotte, NC, USAChicago, IL, USA

Munich, GERMANYParis, FRANCEPhiladelphia, PA, USAPrinceton, NJ, USA (2)Quebec City, QC, CANADAResearch Triangle Park, NC, USASan Diego, CA, USASingapore

Frankfurt, GERMANY High Wycombe, UKKennett Square, PA, USALondon, ON, CANADAMadrid, SPAINMontreal, QC, CANADAMoscow, RUSSIAMumbai, INDIA

BelgiumBrazilCanadaChileCzech RepublicHong Kong

Hungary IndonesiaIrelandIsraelItalyJapan

Field-Based Staff

Clinical Facilities

Bioanalytical Laboratories

PharmaNet

PharmaNet Field-Based Staff

Stockholm, SWEDENSydney, AUSTRALIAToronto, ON, CANADA (2)Trois-Rivieres, QC, CANADAWarsaw, POLANDWashington, DC, USAWilmington, DE, USAZurich, SWITZERLAND

KoreaMexicoPeruShanghaiSouth AfricaTaiwanUnited States

Locations

* As of June 2006

Strong Clinical Development Expertise: Therapeutic Divisions

Oncology

Neuroscience

Cardiovascular

Infectious diseaseOperational Expertise

(Implementation)

Medical Expertise

(Strategy)

Experience and capabilities in high-growth therapeutic areas

Industry-leading Research, Technology and Consulting Services Throughout the Clinical Development Process

Volunteer recruitment

Bioequivalence trials

Protocol development

Project management

Site management and monitoring

Patient recruitment

Phase I–IV studies

Clinical laboratory

Sample analysis

Stability evaluation

Discovery Method development and validation

Documentation

Submission

QA/QC

Safety/pharmacovigilance

Scientific and medical writing

Data management Biostatistics SAS® programming

Efficacy, toxicity, dosage-optimization, market expansion, and agency-mandated studies

Regulatory Statistical Promotional assistance Clinical

Biomarkers

Advisory/safety committee participation

PK/PD modeling

Services and Expertise: Core Services

Phase I Clinical Development ServicesFacilities in Québec City (168 beds) and Montréal, Canada (150 beds)

Bioanalytical Laboratory ServicesQuantitative determination of drugs and/or metabolites in biological matrices such as blood, serum, plasma, or urineLabs in Princeton, NJ; Philadelphia, PA; Québec City and Toronto, Canada; and Barcelona, Spain Supports preclinical, bioavailability and drug metabolism, bioequivalence, Phase I–IV and drug interaction studies

Services and Expertise: Core Services

Late Clinical DevelopmentA complete range of services for drug development and registration

Phases II, III, and IV clinical development servicesData ManagementBiostatisticsRegulatory Affairs Medical AffairsSafety ReportingElectronic SubmissionsWeb-based technologies

Experience in essentially all significant therapeutic areas being pursued by the pharmaceutical industry

Services and Expertise: Core Services

Post Marketing (Phase IIIb-IV) Dedicated professionals with extensive product-development experience in Phase IIIb–IV studiesSpecialists designing and executing programs that meet the highest standards of scientific integrity and regulatory compliance, while meeting commercial objectivesScientific and medical staff work with client teams to extend patent protection and develop:

New indicationsNew formulationsLine extensionsNew dosagesNew strategies to compete with newly introduced productsRx to OTC switchesReinvigoration of aging brands

Enhancing commercial value through scientific expertise

Services and Expertise: Consulting

Dedicated regulatory professionals with international product-development expertise, including senior-level FDA officials from:

Center for Drug Evaluation and Research (CDER)Center for Biologics Evaluation and Research (CBER)Center for Devices and Radiologic Health (CDRH)

Value added services Clinical development plans and strategiescGMP compliance plansIn-licensing evaluationsNew product due diligenceRisk/benefit analysisBest practice assessments

Combination product evaluationsAssistance with preparation of CMC section Medical and regulatory assessments Evaluation of pre-clinical data for acceptability

Services and Expertise: PharmaSoft® IT

PharmaSoft® electronic data capture (EDC) and data management system employed in >50% late stage studies initiated in 2006Facsimile data capture system with interactive character recognition (ICR)Interactive voice response system (IVRS)Serious adverse event systemProject management information system

Easy to use, web-based, 21 CFR Part 11 compliant, efficient

2006 Strategic Priorities – Early Stage

Restore early stage business to historical levels of performanceOptimize mix of generic and branded business

Enhance Phase I capabilities in Montreal

Assess opportunities for cost reductions and operational efficiencies

Leverage custom assay development expertise

New early stage headquarters in Quebec City and associated sale lease-back agreement

Timing of Phase I facility in Toronto

Closing activities in preparation of sale of Florida facilities

2006 Strategic Priorities – Late Stage

Increase penetration of existing client base and expand client base to drive organic growth

Leverage strong development expertise in virtually every therapeutic area with focus on oncology, neurosciences, cardiovascular and infectious diseases

Geographic expansion in Asia, Latin America, Central and Eastern Europe

Build or buy assessments of complementary services at optimal time Medical Imaging

Clinical trial materials management

Central laboratory services targeted at niche applications

Leverage PharmaSoft® IT platform with enhanced marketing investment and/or partnership

2006 Strategic Priorities – Corporate and Financial

Add members to the Board of Directors

Amend credit facility

Sale lease-back of Quebec City facility

How we differentiate PharmaNet Development Group

Proven medical, scientific and regulatory expertise in key therapeutic areas around the world

Strong project management personnel and tools

PharmaSoft®

Unparalleled client service

Dedicated to patient safety

Investment Summary

Diverse Client Base

Global Operations Well Positioned in the CRO Industry

Experienced Management Team

Advanced Technology Platforms

Strong Clinical Development Expertise

Financial StrengthDedicated to patient safety Unparalleled client service

UBS Global Life Sciences Conference________________________

September 26, 2006